A phase I study of cabozantinib (XL184) in patients with renal cell cancer

BACKGROUND: Cabozantinib targets tyrosine kinases including the hepatocyte growth factor receptor (MET) and vascular endothelial growth factor (VEGF) receptor 2, which are important drug targets in renal cell carcinoma (RCC). PATIENTS AND METHODS: This single-arm open-label phase I trial evaluated t...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Ann Oncol
Autors principals: Choueiri, T. K., Pal, S. K., McDermott, D. F., Morrissey, S., Ferguson, K. C., Holland, J., Kaelin, W. G., Dutcher, J. P.
Format: Artigo
Idioma:Inglês
Publicat: Oxford University Press 2014
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6279111/
https://ncbi.nlm.nih.gov/pubmed/24827131
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdu184
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars